Duchenne muscular dystrophy was nominated to be added to the Recommended Uniform Screening Panel (RUSP), a list of disorders that are screened for at birth. This is an important step […]
Sarepta Therapeutics Shares Clinical Data and Integrated Analysis.
Dear Duchenne Community, We are writing to provide some additional information to accompany our press release (attached) this week about the status of the rolling New Drug Application at the […]
Capricor Announces More Good News For CAP-1002
Italfarmaco released positive topline data from their Phase 3 trial in Givinostat, an anti-fibrotic for use in ambulant boys with Duchenne over 6 years old and on a chronic steroid […]
Significant decreases in key biomarkers of muscle damage.
CureDuchenne Ventures is pleased to share that one of our research investments, Code Bio, has announced that have secured $75 million in additional investments to advance their gene therapy programs […]
We’re thrilled to announce that researchers at Nationwide Children’s Hospital have documented the first-ever creation of full-length dystrophin in a human as a response to gene therapy. CureDuchenne has contributed […]
